Phase 1 COVID-19 Immunity - National Core Study
COVID-19 免疫第一阶段 - 国家核心研究
基本信息
- 批准号:MC_PC_20060
- 负责人:
- 金额:$ 999.65万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Intramural
- 财政年份:2021
- 资助国家:英国
- 起止时间:2021 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The magnitude and quality of a person's immune response remains a central determinant of clinical outcome following SARS-CoV-2 infection and vaccines now provide an approach for pandemic control. The NCSi programme is designed to co-ordinate and build on UK investments in understanding COVID-19 immunity. These are based around four themes which seek to predict and manage individual risk, protect against acute infection and late effects of infection, prevent primary infection or re-infection, and prepare for future pandemic challenges.
一个人的免疫反应的程度和质量仍然是SARS-CoV-2感染后临床结果的核心决定因素,疫苗现在提供了一种控制大流行的方法。NCSi计划旨在协调和建立英国在了解COVID-19免疫方面的投资。这四个主题旨在预测和管理个人风险,预防急性感染和感染的后期影响,预防初次感染或再次感染,并为未来的大流行挑战做好准备。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.
- DOI:10.1111/imm.13450
- 发表时间:2022-05
- 期刊:
- 影响因子:6.4
- 作者:
- 通讯作者:
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
- DOI:10.1016/s2468-1253(22)00005-x
- 发表时间:2022-04
- 期刊:
- 影响因子:0
- 作者:Alexander JL;Kennedy NA;Ibraheim H;Anandabaskaran S;Saifuddin A;Castro Seoane R;Liu Z;Nice R;Bewshea C;D'Mello A;Constable L;Jones GR;Balarajah S;Fiorentino F;Sebastian S;Irving PM;Hicks LC;Williams HRT;Kent AJ;Linger R;Parkes M;Kok K;Patel KV;Teare JP;Altmann DM;Boyton RJ;Goodhand JR;Hart AL;Lees CW;Ahmad T;Powell N;VIP study investigators
- 通讯作者:VIP study investigators
Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales.
- DOI:10.1016/j.lanepe.2023.100816
- 发表时间:2024-02
- 期刊:
- 影响因子:20.9
- 作者:Bedston, Stuart;Almaghrabi, Fatima;Patterson, Lynsey;Agrawal, Utkarsh;Woolford, Lana;Anand, Sneha N;Joy, Mark;Crawford, Anna;Goudie, Rosalind;Byford, Rachel;Abbasizanjani, Hoda;Smith, Deb;Laidlaw, Lynn;Akbari, Ashley;Sullivan, Christopher;Bradley, Declan T;Lyons, Ronan A;de Lusignan, Simon;Hobbs, F D Richard;Robertson, Chris;Sheikh, Sir Aziz;Shi, Ting
- 通讯作者:Shi, Ting
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
- DOI:10.1016/s2468-1253(22)00274-6
- 发表时间:2022-11
- 期刊:
- 影响因子:35.7
- 作者:Alexander, James L.;Liu, Zhigang;Sandoval, Diana Munoz;Reynolds, Catherine;Ibraheim, Hajir;Anandabaskaran, Sulak;Saifuddin, Aamir;Seoane, Rocio Castro;Anand, Nikhil;Nice, Rachel;Bewshea, Claire;D'Mello, Andrea;Constable, Laura;Jones, Gareth R.;Balarajah, Sharmili;Fiorentino, Francesca;Sebastian, Shaji;Irving, Peter M.;Hicks, Lucy C.;Williams, Horace R. T.;Kent, Alexandra J.;Linger, Rachel;Parkes, Miles;Kok, Klaartje;Patel, Kamal V.;Teare, Julian P.;Altmann, Daniel M.;Goodhand, James R.;Hart, Ailsa L.;Lees, Charlie W.;Boyton, Rosemary J.;Kennedy, Nicholas A.;Ahmad, Tariq;Powell, Nick
- 通讯作者:Powell, Nick
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study.
- DOI:10.1016/j.jinf.2022.09.004
- 发表时间:2022-11
- 期刊:
- 影响因子:28.2
- 作者:Atti, Ana;Insalata, Ferdinando;Carr, Edward J.;Otter, Ashley D.;Castillo-Olivares, Javier;Wu, Mary;Harvey, Ruth;Howell, Michael;Chan, Andrew;Lyall, Jonathan;Temperton, Nigel;Cantoni, Diego;da Costa, Kelly;Nadesalingam, Angalee;Taylor-Kerr, Andrew;Hettiarachchi, Nipunadi;Tranquillini, Caio;Hewson, Jacqueline;Cole, Michelle J.;Foulkes, Sarah;Munro, Katie;Monk, Edward J. M.;Milligan, Iain D.;Linley, Ezra;Chand, Meera A.;Brown, Colin S.;Islam, Jasmin;Semper, Amanda;Charlett, Andre;Heeney, Jonathan L.;Beale, Rupert;Zambon, Maria;Hopkins, Susan;Brooks, Tim;Hall, Victoria
- 通讯作者:Hall, Victoria
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Moss其他文献
Clonal Populations of CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Patients With Multiple Myeloma and Paraproteinemia
- DOI:
10.1182/blood.v87.8.3297.bloodjournal8783297 - 发表时间:
1996-04-15 - 期刊:
- 影响因子:
- 作者:
Paul Moss;Geraldine Gillespie;Penny Frodsham;John Bell;Hugh Reyburn - 通讯作者:
Hugh Reyburn
Accelerated immune ageing is associated with COVID-19 disease severity
- DOI:
10.1186/s12979-023-00406-z - 发表时间:
2024-01-11 - 期刊:
- 影响因子:5.600
- 作者:
Janet M. Lord;Tonny Veenith;Jack Sullivan;Archana Sharma-Oates;Alex G. Richter;Neil J. Greening;Hamish J. C. McAuley;Rachael A. Evans;Paul Moss;Shona C. Moore;Lance Turtle;Nandan Gautam;Ahmed Gilani;Manan Bajaj;Louise V. Wain;Christopher Brightling;Betty Raman;Michael Marks;Amisha Singapuri;Omer Elneima;Peter J. M. Openshaw;Niharika A. Duggal - 通讯作者:
Niharika A. Duggal
Immunosenescence and Cytomegalovirus: where do we stand after a decade?
- DOI:
10.1186/1742-4933-7-13 - 发表时间:
2010-09-07 - 期刊:
- 影响因子:5.600
- 作者:
Graham Pawelec;Arne Akbar;Peter Beverley;Calogero Caruso;Evelyna Derhovanessian;Tamas Fülöp;Paul Griffiths;Beatrix Grubeck-Loebenstein;Klaus Hamprecht;Gerhard Jahn;Florian Kern;Sven D Koch;Anis Larbi;Andrea B Maier;Derek Macallan;Paul Moss;Sandrine Samson;Jan Strindhall;Emanuelle Trannoy;Mark Wills - 通讯作者:
Mark Wills
University of Birmingham Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
伯明翰大学 B 细胞慢性淋巴细胞白血病疫苗接种患者体内 SARS-CoV-2 δ 变异的中和作用受损
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
H. Parry;Graham McIlroy;R. Bruton;Sarah Damery;G. Tyson;Nicola Logan;Chris Davis;Brian J. Willett;J. Zuo;Myah Ali;Manjit Kaur;Christine Stephens;Dawn Brant;A. Otter;T. McSkeane;Hayley Rolfe;S. Faustini;Alex Richter;Sophie Lee;Farooq Wandroo;S. Shafeek;Guy Pratt;S. Paneesha;Paul Moss - 通讯作者:
Paul Moss
‘From immunosenescence to immune modulation’: a re-appraisal of the role of cytomegalovirus as major regulator of human immune function
- DOI:
10.1007/s00430-019-00612-x - 发表时间:
2019-05-03 - 期刊:
- 影响因子:3.000
- 作者:
Paul Moss - 通讯作者:
Paul Moss
Paul Moss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Moss', 18)}}的其他基金
COVID-19 Immunity - National Core Study (IMM-NCS)
COVID-19 免疫力 - 国家核心研究 (IMM-NCS)
- 批准号:
MC_PC_20031 - 财政年份:2020
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
A UK underpinning platform to study immunology and immunopathology of COVID-19:The UK Coronavirus Immunology Consortium
英国研究 COVID-19 免疫学和免疫病理学的基础平台:英国冠状病毒免疫学联盟
- 批准号:
MR/V028448/1 - 财政年份:2020
- 资助金额:
$ 999.65万 - 项目类别:
Research Grant
University of Birmingham - Proximity to Discovery 2017
伯明翰大学 - Proximity to Discovery 2017
- 批准号:
MC_PC_17183 - 财政年份:2018
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
The T cell immune response to cytomegalovirus across the adult lifecourse
成人生命历程中 T 细胞对巨细胞病毒的免疫反应
- 批准号:
MR/R011230/1 - 财政年份:2018
- 资助金额:
$ 999.65万 - 项目类别:
Research Grant
University of Birmingham – Confidence in Concept 2017
伯明翰大学 — 2017 年概念信心
- 批准号:
MC_PC_17169 - 财政年份:2018
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
University of Birmingham – Continuing Confidence in Concept
伯明翰大学 — 持续对理念充满信心
- 批准号:
MC_PC_16037 - 财政年份:2017
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
Engaging and creating “Influencers” within an academic-industry environment
在学术产业环境中吸引和创造“影响者”
- 批准号:
MC_PC_15048 - 财政年份:2016
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
Placing Discovery Science at the heart of Big Data
将发现科学置于大数据的核心
- 批准号:
MC_PC_15079 - 财政年份:2016
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
University of Birmingham Confidence in Concept
伯明翰大学对概念的信心
- 批准号:
MC_PC_15032 - 财政年份:2016
- 资助金额:
$ 999.65万 - 项目类别:
Intramural
相似国自然基金
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
- 批准号:82370569
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
COVID-19疫情对我国儿童生长发育影响的异质性研究
- 批准号:42371429
- 批准年份:2023
- 资助金额:52.00 万元
- 项目类别:面上项目
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
- 批准号:LQ23A010016
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
- 批准号:82374291
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
COVID-19中线粒体囊泡抑制CD8+T细胞记忆分化的机制研究
- 批准号:82300018
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
COVID-19疫情爆发后武汉地区儿童副流感病毒3型的流行趋势和进化规律研究
- 批准号:n/a
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于 GDF15-IL6 信号轴探究扶正解毒方逆转血管内皮衰老治疗COVID-19的作用与机制
- 批准号:82374392
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
多维不平稳和长记忆性的复杂整值时间序列的建模及其在Covid-19研究中的应用
- 批准号:12301358
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
COVID-19疫苗同源、异源加强剂次细胞免疫与体液免疫效应的前瞻性队列研究
- 批准号:n/a
- 批准年份:2023
- 资助金额:10.0 万元
- 项目类别:省市级项目
基于人源细胞3D培养和精密肺切片技术探讨慢阻肺患者COVID-19易感机制研究
- 批准号:LY23H190003
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Studentship Programs
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
CoVPN 3008 COVID-19 mRNA 疫苗在 SARS-CoV-2 变异关注地区的 3 期、多中心、随机、功效研究
- 批准号:
10493538 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
SBIR Phase II: Facilitating Early Childhood Teacher and Family Engagement During COVID-19
SBIR 第二阶段:在 COVID-19 期间促进幼儿教师和家庭的参与
- 批准号:
2151349 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Cooperative Agreement
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II
社区参与的针对服务不足和/或弱势群体的 COVID-19 检测研究第二阶段
- 批准号:
10544758 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II
社区参与的针对服务不足和/或弱势群体的 COVID-19 检测研究第二阶段
- 批准号:
10447463 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
SBIR Phase II: Machine Learning for Rapid Automated Viral Infectivity Assays (COVID-19)
SBIR 第二阶段:用于快速自动化病毒感染性检测的机器学习 (COVID-19)
- 批准号:
2136850 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Cooperative Agreement
STTR Phase I: Broad Spectrum Antimicrobial Surface Coating (COVID-19)
STTR 第一阶段:广谱抗菌表面涂层 (COVID-19)
- 批准号:
2112033 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Standard Grant
SBIR Phase I: A platform for simulating the combined effect of human behavior and environment on airborne infectious spread (COVID-19)
SBIR 第一阶段:模拟人类行为和环境对空气传播传染病(COVID-19)综合影响的平台
- 批准号:
2151672 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Standard Grant
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别:
Studentship Programs
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
CoVPN 3003 评估 Ad26.COV2.S 在 18 岁及以上成年人中预防 SARS-CoV-2 介导的 COVID-19 的功效和安全性的 3 期研究 LC 3
- 批准号:
10570748 - 财政年份:2022
- 资助金额:
$ 999.65万 - 项目类别: